Targeted delivery of LXR-agonists to atherosclerotic lesions mediated by polydiacetylene micelles

Nanoscale. 2023 Nov 30;15(46):18864-18870. doi: 10.1039/d3nr04778d.

Abstract

We report the development of compact and stabilized micelles incorporating a synthetic LXR agonist prodrug for the passive targeting of atherosclerotic lesions and therapeutic intervention. In vivo studies showed that the nanohybrid micelles exhibited favorable pharmacokinetics/biodistribution and were able to upregulate, to some extent, LXR target genes with no alteration of lipid metabolism.

MeSH terms

  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / pathology
  • Humans
  • Liver X Receptors / therapeutic use
  • Micelles*
  • Tissue Distribution

Substances

  • Micelles
  • polydiacetylene
  • Liver X Receptors